肾脏累及的弥漫性大B细胞淋巴瘤患者临床病理特征

R733.4; 目的·探究肾脏累及的弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者的临床病理特征,包括临床基本信息、病理特征、基因突变谱与预后相关因素等.方法·回顾性分析2005年7月—2021年11月上海交通大学医学院附属瑞金医院收治的149例肾脏累及的DLBCL患者的临床资料,包括治疗方案、疗效评价及分期等,并采用靶向测序(54个淋巴瘤相关基因)评估患者的基因突变情况.基于患者资料进行生存和预后因素分析.结果·在149例DLBCL肾脏累及的患者中,有87例患者(58.4%)年龄>60岁,121例患者(81.2%)Ann Arbor分...

Full description

Saved in:
Bibliographic Details
Published in上海交通大学学报(医学版) Vol. 44; no. 9; pp. 1162 - 1168
Main Authors 王博恩, 陈思远, 施晴, 张慕晨, 易红梅, 董磊, 王黎, 程澍, 许彭鹏, 赵维莅
Format Journal Article
LanguageChinese
Published 上海交通大学医学院附属瑞金医院血液科,医学基因组学国家重点试验室,上海血液学研究所,上海 200025 28.09.2024
Subjects
Online AccessGet full text
ISSN1674-8115
DOI10.3969/j.issn.1674-8115.2024.09.011

Cover

Abstract R733.4; 目的·探究肾脏累及的弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者的临床病理特征,包括临床基本信息、病理特征、基因突变谱与预后相关因素等.方法·回顾性分析2005年7月—2021年11月上海交通大学医学院附属瑞金医院收治的149例肾脏累及的DLBCL患者的临床资料,包括治疗方案、疗效评价及分期等,并采用靶向测序(54个淋巴瘤相关基因)评估患者的基因突变情况.基于患者资料进行生存和预后因素分析.结果·在149例DLBCL肾脏累及的患者中,有87例患者(58.4%)年龄>60岁,121例患者(81.2%)Ann Arbor分期为Ⅲ~Ⅳ期,27例患者(18.1%)美国东部肿瘤协作组评分≥2分,121例患者(81.2%)血清乳酸脱氢酶(lactate dehydrogenase,LDH)高于正常上限,111例患者(74.5%)至少存在2个以上淋巴结外器官受累,131例患者(87.9%)国际预后指数≥2分.患者的5年总生存率和5年无进展生存率分别为52.2%和50.4%.在病理特征中,145例患者(97.3%)诊断为非特指型DLBCL.按Hans分型,39例患者(26.2%)属生发中心亚型.在可评估疗效的144例患者中,87例(60.4%)患者取得完全缓解.此外,单因素分析显示:血清LDH升高是肾脏累及的DLBCL患者总体生存时间(P=0.048)和无进展生存时间(P=0.033)的不良预后因素;75例肾脏累及的DLBCL患者的靶向测序显示PIM1(n=23,31%)、MYD88(n=22,29%)、CD79B(n=21,28%)和KMT2D(n=18,24%)存在高频突变,其中CD79B突变与较差的总体生存时间相关(P=0.034).结论·肾脏累及的DLBCL患者临床特征中血清LDH升高与不良预后有关,基因突变谱中CD79B突变与不良预后有关.
AbstractList R733.4; 目的·探究肾脏累及的弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者的临床病理特征,包括临床基本信息、病理特征、基因突变谱与预后相关因素等.方法·回顾性分析2005年7月—2021年11月上海交通大学医学院附属瑞金医院收治的149例肾脏累及的DLBCL患者的临床资料,包括治疗方案、疗效评价及分期等,并采用靶向测序(54个淋巴瘤相关基因)评估患者的基因突变情况.基于患者资料进行生存和预后因素分析.结果·在149例DLBCL肾脏累及的患者中,有87例患者(58.4%)年龄>60岁,121例患者(81.2%)Ann Arbor分期为Ⅲ~Ⅳ期,27例患者(18.1%)美国东部肿瘤协作组评分≥2分,121例患者(81.2%)血清乳酸脱氢酶(lactate dehydrogenase,LDH)高于正常上限,111例患者(74.5%)至少存在2个以上淋巴结外器官受累,131例患者(87.9%)国际预后指数≥2分.患者的5年总生存率和5年无进展生存率分别为52.2%和50.4%.在病理特征中,145例患者(97.3%)诊断为非特指型DLBCL.按Hans分型,39例患者(26.2%)属生发中心亚型.在可评估疗效的144例患者中,87例(60.4%)患者取得完全缓解.此外,单因素分析显示:血清LDH升高是肾脏累及的DLBCL患者总体生存时间(P=0.048)和无进展生存时间(P=0.033)的不良预后因素;75例肾脏累及的DLBCL患者的靶向测序显示PIM1(n=23,31%)、MYD88(n=22,29%)、CD79B(n=21,28%)和KMT2D(n=18,24%)存在高频突变,其中CD79B突变与较差的总体生存时间相关(P=0.034).结论·肾脏累及的DLBCL患者临床特征中血清LDH升高与不良预后有关,基因突变谱中CD79B突变与不良预后有关.
Abstract_FL Objective·To analyze the clinicopathologic characteristics of patients with kidney-involved diffuse large B-cell lymphoma(DLBCL),including clinical characteristics,pathological characteristics,gene mutation profiles,and prognostic factors.Methods·One hundred and forty-nine patients with kidney-involved DLBCL,admitted to Ruijin Hospital,Shanghai Jiao Tong University School of Medicine from July 2005 to November 2021,were retrospectively analyzed for their clinicopathological data,survival and prognostic factors,which included therapeutic methods,clinical outcomes,staging,etc.Gene mutation profiles were evaluated by targeted sequencing of 54 lymphoma-related genes.Prognostic factors were also analyzed based on the information mentioned above.Results·A total of 149 kidney-involved DLBCL cases were included,of which 89 patients(58.4%)were aged over sixty,121 patients(81.2%)were staged Ann Arbor Ⅲ?Ⅳ,27 patients(18.1%)had an Eastern Cooperative Oncology Group(ECOG)performance status of two or more,121 patients(81.2%)had elevated serum lactate dehydrogenase(LDH)level,111 patients(74.5%)had extranodal invasion in at least two organs and 131 patients(87.9%)scored over 2 points on the international prognosis index(IPI).The estimated 5-year overall survival(OS)rate and progression-free survival(PFS)rate of kidney-involved DLBCL patients were 52.2%and 50.4%respectively.Univariate analysis revealed that elevated serum LDH levels were an adverse prognostic factor for both OS(P=0.048)and PFS(P=0.033).In pathological characteristics,145 patients(97.3%)belonged to DLBCL,not otherwise specified(NOS)and 39 patients(26.3%)belonged to germinal center B-cell(GCB)according to Hans classification.Among 144 patients who could be evaluated for clinical outcomes,87 patients(60.4%)got complete response(CR).Targeted sequencing data from 75 kidney-involved DLBCL patients showed high mutation frequency in PIM1(n=23,31%),MYD88(n=22,29%),CD79B(n=21,28%)and KMT2D(n=18,24%),with CD79B mutation indentified as an adverse prognostic factor for OS in patients with kidney-involved DLBCL(P=0.034).Conclusion·Elevated serum LDH level is an adverse prognostic factor in patients with kidney-involved DLBCL.The prognosis of patients with CD79B mutations is poor.
Author 张慕晨
许彭鹏
赵维莅
王博恩
陈思远
董磊
易红梅
施晴
王黎
程澍
AuthorAffiliation 上海交通大学医学院附属瑞金医院血液科,医学基因组学国家重点试验室,上海血液学研究所,上海 200025
AuthorAffiliation_xml – name: 上海交通大学医学院附属瑞金医院血液科,医学基因组学国家重点试验室,上海血液学研究所,上海 200025
Author_FL SHI Qing
CHENG Shu
XU Pengpeng
DONG Lei
ZHAO Weili
CHEN Siyuan
YI Hongmei
WANG Boen
ZHANG Muchen
WANG Li
Author_FL_xml – sequence: 1
  fullname: WANG Boen
– sequence: 2
  fullname: CHEN Siyuan
– sequence: 3
  fullname: SHI Qing
– sequence: 4
  fullname: ZHANG Muchen
– sequence: 5
  fullname: YI Hongmei
– sequence: 6
  fullname: DONG Lei
– sequence: 7
  fullname: WANG Li
– sequence: 8
  fullname: CHENG Shu
– sequence: 9
  fullname: XU Pengpeng
– sequence: 10
  fullname: ZHAO Weili
Author_xml – sequence: 1
  fullname: 王博恩
– sequence: 2
  fullname: 陈思远
– sequence: 3
  fullname: 施晴
– sequence: 4
  fullname: 张慕晨
– sequence: 5
  fullname: 易红梅
– sequence: 6
  fullname: 董磊
– sequence: 7
  fullname: 王黎
– sequence: 8
  fullname: 程澍
– sequence: 9
  fullname: 许彭鹏
– sequence: 10
  fullname: 赵维莅
BookMark eNo9j7tKA0EYRqeIYIx5CzvZ9Z_r7pQavEHARusw4-5oomzARYxdjEnAWMROsbAxksLCZiFeQp7G3dnHUFGsPjjFOXwLqBA1oxChJQwulUKuNNx6HEcuFh5zfIy5S4AwF6QLGBdQ8Z_Po3Ic1zWAJyQlHhRRJe_M8u7QJi_pcGDvu-n0KZs-Z-1xOhqv2Y9-fvmQTa7TSWLvRlnnMW_3Pl-T9H1gb3v2pm-v3tLZxSKaM-o4Dst_W0J7G-u7lS2nurO5XVmtOjEGQRyiNMZGUxBMA1U6kJyFkpmAaR84U0rth8LDoIykXAUCGx4KRgD7vubcKFpCy7_eMxUZFR3UGs3Tk-i7WIsPg_D8KGi19M9xkIAJ_QK5z2mz
ClassificationCodes R733.4
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3969/j.issn.1674-8115.2024.09.011
DatabaseName Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
DocumentTitle_FL Clinicopathologic characteristics of patients with kidney-involved diffuse large B-cell lymphoma
EndPage 1168
ExternalDocumentID shdeykdxxb202409012
GroupedDBID -05
2B.
4A8
92I
93N
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CIEJG
GROUPED_DOAJ
PSX
TCJ
ID FETCH-LOGICAL-s1062-2ab11fb3064b03abd954e94fd4b8054aaace6710af935ad61f5e6420188b55fa3
ISSN 1674-8115
IngestDate Thu May 29 03:59:27 EDT 2025
IsPeerReviewed false
IsScholarly true
Issue 9
Keywords 基因突变谱
肾脏
kidney
gene mutation profile
临床特征
clinic pathologic characteristics
diffuse large B-cell lymphoma(DLBCL)
prognosis
弥漫性大B细胞淋巴瘤
预后分析
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-s1062-2ab11fb3064b03abd954e94fd4b8054aaace6710af935ad61f5e6420188b55fa3
PageCount 7
ParticipantIDs wanfang_journals_shdeykdxxb202409012
PublicationCentury 2000
PublicationDate 2024-09-28
PublicationDateYYYYMMDD 2024-09-28
PublicationDate_xml – month: 09
  year: 2024
  text: 2024-09-28
  day: 28
PublicationDecade 2020
PublicationTitle 上海交通大学学报(医学版)
PublicationTitle_FL Journal of Shanghai Jiaotong University(Medical Science)
PublicationYear 2024
Publisher 上海交通大学医学院附属瑞金医院血液科,医学基因组学国家重点试验室,上海血液学研究所,上海 200025
Publisher_xml – name: 上海交通大学医学院附属瑞金医院血液科,医学基因组学国家重点试验室,上海血液学研究所,上海 200025
SSID ssib007693270
ssib021364667
ssib051367862
ssib006260104
ssib008858007
ssib005076848
ssib006702980
ssib036439378
ssj0001538017
Score 2.407938
Snippet R733.4; 目的·探究肾脏累及的弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者的临床病理特征,包括临床基本信息、病理特征、基因突变谱与预后相关因素等.方...
SourceID wanfang
SourceType Aggregation Database
StartPage 1162
Title 肾脏累及的弥漫性大B细胞淋巴瘤患者临床病理特征
URI https://d.wanfangdata.com.cn/periodical/shdeykdxxb202409012
Volume 44
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  issn: 1674-8115
  databaseCode: DOA
  dateStart: 20100101
  customDbUrl:
  isFulltext: true
  dateEnd: 99991231
  titleUrlDefault: https://www.doaj.org/
  omitProxy: true
  ssIdentifier: ssj0001538017
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  issn: 1674-8115
  databaseCode: ABDBF
  dateStart: 20160901
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  isFulltext: true
  dateEnd: 99991231
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  omitProxy: true
  ssIdentifier: ssib006260104
  providerName: EBSCOhost
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1NaxQxdChbEC-iqPhZemiOW3cyk0xyzOzOUgQ9tdBbmXRnLAgr2BZqT7W2Beuh3hQPXqz04MFLoX6U_hYP7sfP8L03sztTu0gtLMub5H3mZZP3spPEcaZgzgo0D3i1JWNZ9W3aqlrtY9YKI3JqlVR0bsGjx3Jmzn84L-bHKr9Kby2trtjpxfWR-0ou4lUoA7_iLtn_8OyQKRQADP6Fb_AwfJ_LxyxSTHEWRgRAVNhkUcBCnxkABD4qgyXaYC2UhHVmBIskASECqsZMgFUGqIKQ6EOmJHH0mI4IO2AqJHrijhwVEiA9Z8Yj5BpTwNpnoSIcQDYD8QFVAVAjzvCoWagJJ2LZXSqDADnngIQglyRiiSFxmt7LMEN1CWgwI0uARFo0solGKkUNUUejChxSAKsynOFaCNVEua2qQaKAn8tMCUUznRFT4-kGGh82ma4XKJJpUL5BAFjqFzWZC2pELJgWOYpR5dUX7uOrIvludvy9XLxR_raclDd8YEXmJ5fcDO7JACgnuCAfUoHXXRSHasCHI5UhZF4fJQ5MbKKeCIRkd9a9_NM4ITUWlETINlMAmh-9wamjKOzR2FqghkEpGTLYi3LPNs5ZPUu-BzU0dWKjSZyk3lAbyQpP3Kxle-bzqVsGflW52ebgwdyenS2aj2G6NFG7bh4EJINHNSqg8LTUFFCgiOmhiGnsCnQ-ch4pnD6yfXmplbx42lpbs4hXg5AbgsRxDnFHreKMm7ARNos5kP4KL82B_PQSiQzwkoRiTsW7S3lpjlVKQM43TCG460lfFimFhxmHVxzZJ_CIRpUfEZqdpOBBkEp3UA2su4RDOJn-4F-G0zbHdhq3n5Qi8tmrzpU8lZ402bh4zRlbX7ru1PubJ_2tvd7h187ebu_DVuf4c_f4S3fjoLN_EPZ-7vRffewevekcHfbe73c3P_U3tn9_O-z82O292-693em9_t45eXnDmWtGs_WZan5RTHXZhQar8ti6bmpxMQUsjm1LCz_RftryrYKUNI7jxURCKhWn2hNxS7qpSKQPqY9SVog09m46lfazdnLLmfSta1NueSIS12_FVgkdCJ7I1ArXBiK47UzlRi_kE8Hywgh33zkf2l3ncjGo3HMqK89Xk_uQ5KzYibyfTNAi4R-jovEn
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E8%82%BE%E8%84%8F%E7%B4%AF%E5%8F%8A%E7%9A%84%E5%BC%A5%E6%BC%AB%E6%80%A7%E5%A4%A7B%E7%BB%86%E8%83%9E%E6%B7%8B%E5%B7%B4%E7%98%A4%E6%82%A3%E8%80%85%E4%B8%B4%E5%BA%8A%E7%97%85%E7%90%86%E7%89%B9%E5%BE%81&rft.jtitle=%E4%B8%8A%E6%B5%B7%E4%BA%A4%E9%80%9A%E5%A4%A7%E5%AD%A6%E5%AD%A6%E6%8A%A5%EF%BC%88%E5%8C%BB%E5%AD%A6%E7%89%88%EF%BC%89&rft.au=%E7%8E%8B%E5%8D%9A%E6%81%A9&rft.au=%E9%99%88%E6%80%9D%E8%BF%9C&rft.au=%E6%96%BD%E6%99%B4&rft.au=%E5%BC%A0%E6%85%95%E6%99%A8&rft.date=2024-09-28&rft.pub=%E4%B8%8A%E6%B5%B7%E4%BA%A4%E9%80%9A%E5%A4%A7%E5%AD%A6%E5%8C%BB%E5%AD%A6%E9%99%A2%E9%99%84%E5%B1%9E%E7%91%9E%E9%87%91%E5%8C%BB%E9%99%A2%E8%A1%80%E6%B6%B2%E7%A7%91%2C%E5%8C%BB%E5%AD%A6%E5%9F%BA%E5%9B%A0%E7%BB%84%E5%AD%A6%E5%9B%BD%E5%AE%B6%E9%87%8D%E7%82%B9%E8%AF%95%E9%AA%8C%E5%AE%A4%2C%E4%B8%8A%E6%B5%B7%E8%A1%80%E6%B6%B2%E5%AD%A6%E7%A0%94%E7%A9%B6%E6%89%80%2C%E4%B8%8A%E6%B5%B7+200025&rft.issn=1674-8115&rft.volume=44&rft.issue=9&rft.spage=1162&rft.epage=1168&rft_id=info:doi/10.3969%2Fj.issn.1674-8115.2024.09.011&rft.externalDocID=shdeykdxxb202409012
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fshdeykdxxb%2Fshdeykdxxb.jpg